公开(公告)号：US20240245694A1

公开(公告)日：2024-07-25

申请号：US18483651

申请日：2023-10-10

Applicant: Novartis AG

Inventor： Vincent BORDAS ,  Markus FUREGATI ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Ziyue HONG ,  Fabio LIMA ,  Fatma LIMAM ,  Henrik MOEBITZ ,  Sandro NOCITO ,  Niko SCHMIEDEBERG ,  Joseph SCHOEPFER ,  Ross Sinclair STRANG ,  Frédéric ZECRI ,  Huangchao YU ,  Yong ZHANG ,  Xinkan YANG ,  Sisi ZHANG ,  Wei LI

IPC: A61K31/5377 ,  A61K31/519 ,  C07D487/14 ,  C07D519/00

CPC classification number: A61K31/5377 ,  A61K31/519 ,  C07D487/14 ,  C07D519/00

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I):




wherein R1, R2, R3, x, R4, R5, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

公开(公告)号：US20240360118A1

公开(公告)日：2024-10-31

申请号：US18506164

申请日：2023-11-10

Applicant: Novartis AG

Inventor： Vincent BORDAS ,  Jvan BRUN ,  Andrea DECKER ,  Markus FUREGATI ,  Geoffrey GOGNIAT ,  Wanben GONG ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Philipp HOLZER ,  Fatma LIMAM ,  Henrik MÖBITZ ,  Sandro NOCITO ,  Simone PLATTNER ,  Niko SCHMIEDEBERG ,  Joseph SCHOEPFER ,  Jessica SOTO ,  Ross Sinclair STRANG ,  Shuping YAO ,  Huangchao YU ,  Frédéric ZECRI ,  Sisi ZHANG

IPC: C07D413/14 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D405/14 ,  C07B2200/13

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I):




wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

公开(公告)号：US20230046859A1

公开(公告)日：2023-02-16

申请号：US17824407

申请日：2022-05-25

Applicant: NOVARTIS AG

Inventor： Vincent BORDAS ,  Jvan BRUN ,  Andrea DECKER ,  Markus FUREGATI ,  Geoffrey GOGNIAT ,  Wanben GONG ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Philipp HOLZER ,  Fatma LIMAM ,  Henrik MÖBITZ ,  Sandro NOCITO ,  Simone PLATTNER ,  Niko SCHMIEDEBERG ,  Joseph SCHOEPFER ,  Jessica SOTO ,  Ross Sinclair STRANG ,  Shuping YAO ,  Huangchao YU ,  Frédéric ZECRI ,  Sisi ZHANG

IPC: C07D413/14 ,  C07D401/14 ,  C07D405/14

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

公开(公告)号：US20190177324A1

公开(公告)日：2019-06-13

申请号：US16323668

申请日：2017-09-28

Applicant: Novartis AG

Inventor： Anthony CASAREZ ,  Markus FUREGATI ,  Guido KOCH ,  Xiaodong LIN ,  Flavio OSSOLA ,  Folkert RECK ,  Robert Lowell SIMMONS ,  Qingming ZHU

IPC: C07D471/18 ,  A61P31/04 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/427 ,  A61K31/546 ,  A61K31/407 ,  A61K31/496

Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.

公开(公告)号：US20180086762A1

公开(公告)日：2018-03-29

申请号：US15718571

申请日：2017-09-28

Applicant: Novartis AG

Inventor： Anthony CASAREZ ,  Markus FUREGATI ,  Guido KOCH ,  Xiaodong LIN ,  Flavio OSSOLA ,  Folkert RECK ,  Robert Lowell SIMMONS ,  Qingming ZHU

IPC: C07D471/18 ,  A61K31/439 ,  A61K31/431 ,  A61K31/427 ,  A61K31/546 ,  A61K31/407 ,  A61K31/496

CPC classification number: C07D471/18 ,  A61K31/407 ,  A61K31/427 ,  A61K31/431 ,  A61K31/439 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/535 ,  A61K31/546 ,  A61K31/551 ,  A61K45/06 ,  A61P31/04 ,  C07B2200/13 ,  A61K2300/00

Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.